Psilocybin and Lithium: Why This Combination Is Unsafe
Lithium is the clearest dangerous interaction with psilocybin in the published literature. Multiple case reports and the largest self-report analysis to date link the combination to tonic-clonic seizures. Every clinical trial contraindicates it. This guide lays out what the evidence actually shows, what the likely mechanism is, and what to do if you are on lithium and considering psilocybin therapy.
Published
Chief Bear · ~8 min read
Quick Answer
Lithium combined with psilocybin is linked to seizures in published case reports (Nayak et al., 2021, Psychopharmacology). Lithium is an absolute exclusion criterion in every modern psilocybin clinical trial. If you are currently on lithium, do not use psilocybin. Any transition away from lithium to access psilocybin therapy must be managed by a psychiatrist — lithium treats conditions (usually bipolar disorder) that also carry independent contraindications for psilocybin.
What the Evidence Actually Shows
The psilocybin-lithium interaction stands out in the psychedelic-safety literature because the clinical signal is unusually clear for an interaction that has never been studied prospectively in humans. The evidence comes from three sources, and all three point the same direction.
First — individual case reports in the psychiatric literature. Isolated reports describe previously healthy adults experiencing tonic-clonic seizures after taking psilocybin (or LSD) while on therapeutic-dose lithium. These are the kind of cases that clinicians flag as a signal worth tracking, not the kind that can prove causation in isolation, but the pattern is consistent: the seizures are generalized, they occur during or shortly after the psychedelic experience, and they do not fit the background rate of seizures in the underlying population.
Second — the Nayak 2021 systematic analysis. Nayak, Javed, and colleagues (2021, Psychopharmacology) reviewed the largest available self-reported psychedelic database — Erowid and related corpora — for medication interactions. Psilocybin-plus-lithium and LSD-plus-lithium produced a disproportionately high rate of seizures and severe adverse physical events compared to every other psychiatric-medication combination examined. The absolute numbers were small (the database contains relatively few lithium users), but the signal was orders of magnitude above baseline.
Third — clinical trial exclusion criteria. Every psilocybin trial conducted under FDA oversight (Compass COMP360 program, Usona Institute PSIL201, Johns Hopkins, NYU, Imperial College London) excludes participants on lithium. Trial safety committees have reviewed the available evidence and decided that enrolling lithium users is not acceptable risk. These committees include neurologists and pharmacologists who examined exactly this question.
None of these lines of evidence is a randomized controlled trial — the question cannot ethically be studied that way. But the combined weight of individual clinician reports, self-report aggregate data, and safety-committee consensus is as close to “established dangerous interaction” as a non-prospective dataset gets.
The Nayak 2021 Analysis in Detail
The Nayak et al. paper is the single most-cited source on this interaction and worth understanding in its own right. The authors systematically reviewed user-submitted psychedelic experience reports on Erowid for any mention of a concurrent psychiatric medication. They extracted reports involving lithium, tricyclic antidepressants, SSRIs, MAOIs, benzodiazepines, and stimulants, and scored each report for the presence of severely negative physical or psychological outcomes.
For psilocybin + lithium specifically, they identified 19 reports. Of those 19, 9 described severely negative physical reactions including tonic-clonic seizures, loss of consciousness, or hospitalization. For LSD + lithium (similar mechanism), the rate was similar. By contrast, reports of psilocybin with SSRIs — which some readers assume is more dangerous — showed overwhelmingly mild or no interaction, mostly blunting.
Self-report data skews toward dramatic events (people post reports when something went wrong), and Erowid's corpus is not representative of the lithium-using population. The analysis cannot prove causation. What it can do — and what it does — is demonstrate a signal large enough to force the question into clinical-trial-exclusion territory, which is exactly what has happened.
Nayak et al. conclude the paper with a direct recommendation against combining classic psychedelics with lithium. That recommendation has been adopted by MAPS, the Usona Institute, Compass Pathways, and every harm-reduction reference that has updated since 2021.
Why It Happens — The Likely Mechanism
The mechanistic explanation is less settled than the clinical signal. Lithium's pharmacology is unusually broad and not well-characterized even after 70 years of clinical use. The leading candidate mechanisms for the psilocybin interaction involve lithium's effects on neuronal excitability rather than any direct action on serotonin receptors.
- Inositol monophosphatase (IMPase) inhibition. Lithium depletes neuronal free inositol, which alters second-messenger cascades downstream of multiple G-protein-coupled receptors — including the 5-HT2A receptor that psilocin activates. Altered downstream signaling could modify cortical excitability enough to lower seizure threshold during a strong 5-HT2A challenge.
- GSK-3β modulation. Lithium inhibits glycogen synthase kinase-3β, part of a signaling cascade that regulates neuroplasticity and neuronal excitability. Chronic GSK-3β inhibition combined with the plasticity signal psilocybin produces may create conditions that favor ictal activity.
- Altered sodium gradients and neuronal depolarization. Lithium substitutes partially for sodium at neuronal membranes, subtly changing depolarization dynamics. Under a strong 5-HT2A agonist, the baseline shift may matter.
- Lowered seizure threshold from lithium itself. Lithium toxicity (serum > 1.5 mEq/L) is independently associated with seizures. Even at therapeutic levels, lithium may lower the threshold at which other pro-convulsant stressors trigger ictal activity, and psilocybin's cortical activation qualifies as one such stressor.
These are hypotheses. The clinical rule does not depend on which is correct. You do not need to understand the mechanism to follow the contraindication.
Bipolar Disorder — Two Reasons to Avoid
Most people on lithium are on it for bipolar disorder — Type I for the majority, Type II for a smaller subset, and occasionally treatment-resistant unipolar depression or schizoaffective disorder. For psilocybin, this creates two separate layers of contraindication.
- Lithium itself. The seizure risk discussed above.
- The underlying bipolar diagnosis. Bipolar I is an exclusion criterion in virtually every psilocybin clinical trial because of the risk of mania induction — a strong serotonergic stimulus can trigger a manic episode in someone prone to them (Gard et al., 2024, Journal of Affective Disorders). Bipolar II is sometimes included in more recent research protocols under close monitoring. Unipolar depression without a bipolar history does not carry the mania risk.
This is why stopping lithium to access psilocybin therapy is not a simple algebra of “wait 7 days for clearance and dose.” Even with lithium fully cleared, the underlying condition remains, and the condition itself may be the reason psilocybin is off the table. See our psilocybin for depression page for the clinical-trial population that psilocybin therapy is actually being studied in (unipolar treatment-resistant depression, not bipolar).
If You Are Considering Stopping Lithium
Stopping lithium is a major psychiatric decision. It is not a self-managed transition. Abrupt lithium discontinuation in bipolar disorder substantially increases the risk of manic or depressive relapse, and in bipolar I, the risk of suicidal ideation. This section describes the general shape of a supervised transition; the specifics belong with a psychiatrist who knows your history.
Pharmacokinetically, lithium itself clears the body within about a week in most adults — serum half-life is approximately 24 hours, and elimination is complete 4–7 days after the last dose. That would suggest a simple timeline. The timeline that matters, though, is the condition timeline, not the drug timeline.
A supervised transition typically looks like:
- Months of psychiatric evaluation to confirm stability and assess whether lithium is the right long-term medication at all
- A gradual cross-taper to an alternative mood stabilizer that is psilocybin-compatible (see the next section) — or a decision that staying on lithium is the safer long-term choice
- An extended stability period on the alternative medication before any psilocybin session is considered
- Close monitoring for mood episodes across the entire transition
For most people on long-term lithium for bipolar I, the honest answer from a thoughtful psychiatrist is that psilocybin is not an appropriate treatment at this time, regardless of enthusiasm for the field. That is not a permanent answer — the research will continue to mature — but it is the answer in 2026.
Alternatives Worth Discussing With a Psychiatrist
None of these are recommendations. They are the categories of alternatives a psychiatrist might consider if someone with unipolar treatment-resistant depression has been managed with lithium augmentation and wants to explore psilocybin therapy.
- Lamotrigine. A mood stabilizer often used in bipolar II and augmentation settings. It is not contraindicated with psilocybin in the same way lithium is, though data on the combination is limited. Lamotrigine does lower seizure threshold less aggressively than lithium.
- Atypical antipsychotics at mood-stabilizing doses. Quetiapine, lurasidone, and others. These will block psilocybin effects through direct 5-HT2A antagonism — a different problem than lithium's seizure risk, but incompatible with psilocybin therapy while taken.
- Ketamine or esketamine (Spravato). An entirely different pharmacological pathway that has FDA approval for treatment-resistant depression and does not interact with lithium in the same way. See our psilocybin vs ketamine comparison for the full contrast.
- Staying on lithium. For someone with well-controlled bipolar I, the right answer is often to stay on lithium and let psilocybin remain off the table. The treatment someone already has working is usually more valuable than the treatment they might try.
Key Takeaways
- Do not combine psilocybin and lithium. Seizure risk is documented in case reports and the largest self-report analysis (Nayak et al., 2021).
- Every clinical trial contraindicates it. Lithium is an exclusion criterion in Compass, Usona, Johns Hopkins, NYU, and Imperial College trials.
- The mechanism is not fully settled, but the clinical signal is. Inositol depletion, GSK-3β modulation, and altered neuronal excitability are the leading candidate explanations.
- Two layers of contraindication if you have bipolar I. Lithium is contraindicated, and so is the underlying condition (mania-induction risk).
- Transitioning off lithium is a psychiatric decision, not a timeline problem. Do not self-taper to access psilocybin therapy. The underlying condition dictates the plan.